Atea Pharmaceuticals (AVIR) Competitors $3.14 -0.16 (-4.85%) Closing price 04:00 PM EasternExtended Trading$3.20 +0.06 (+2.04%) As of 06:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AVIR vs. MLYS, PHAR, NUVB, SYRE, CRON, ORIC, ATAI, PRAX, UPB, and URGNShould you be buying Atea Pharmaceuticals stock or one of its competitors? The main competitors of Atea Pharmaceuticals include Mineralys Therapeutics (MLYS), Pharming Group (PHAR), Nuvation Bio (NUVB), Spyre Therapeutics (SYRE), Cronos Group (CRON), Oric Pharmaceuticals (ORIC), atai Life Sciences (ATAI), Praxis Precision Medicines (PRAX), Upstream Bio (UPB), and Urogen Pharma (URGN). These companies are all part of the "pharmaceutical products" industry. Atea Pharmaceuticals vs. Its Competitors Mineralys Therapeutics Pharming Group Nuvation Bio Spyre Therapeutics Cronos Group Oric Pharmaceuticals atai Life Sciences Praxis Precision Medicines Upstream Bio Urogen Pharma Mineralys Therapeutics (NASDAQ:MLYS) and Atea Pharmaceuticals (NASDAQ:AVIR) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation. Is MLYS or AVIR more profitable? Atea Pharmaceuticals' return on equity of -32.55% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Mineralys TherapeuticsN/A -70.44% -65.51% Atea Pharmaceuticals N/A -32.55%-30.47% Do analysts recommend MLYS or AVIR? Mineralys Therapeutics currently has a consensus target price of $43.50, indicating a potential upside of 17.25%. Atea Pharmaceuticals has a consensus target price of $6.00, indicating a potential upside of 91.08%. Given Atea Pharmaceuticals' higher probable upside, analysts clearly believe Atea Pharmaceuticals is more favorable than Mineralys Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mineralys Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do institutionals and insiders have more ownership in MLYS or AVIR? 84.5% of Mineralys Therapeutics shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 25.6% of Mineralys Therapeutics shares are owned by insiders. Comparatively, 18.1% of Atea Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility and risk, MLYS or AVIR? Mineralys Therapeutics has a beta of -0.29, indicating that its stock price is 129% less volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Which has stronger valuation & earnings, MLYS or AVIR? Mineralys Therapeutics is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMineralys TherapeuticsN/AN/A-$177.81M-$3.56-10.42Atea PharmaceuticalsN/AN/A-$168.38M-$1.61-1.95 Does the media refer more to MLYS or AVIR? In the previous week, Mineralys Therapeutics had 24 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 27 mentions for Mineralys Therapeutics and 3 mentions for Atea Pharmaceuticals. Mineralys Therapeutics' average media sentiment score of 0.98 beat Atea Pharmaceuticals' score of 0.75 indicating that Mineralys Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mineralys Therapeutics 10 Very Positive mention(s) 6 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atea Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAtea Pharmaceuticals beats Mineralys Therapeutics on 7 of the 12 factors compared between the two stocks. Get Atea Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AVIR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVIR vs. The Competition Export to ExcelMetricAtea PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$261.88M$3.12B$5.79B$10.15BDividend YieldN/A2.32%5.69%4.61%P/E RatioN/A21.3074.5925.92Price / SalesN/A240.30449.5483.33Price / CashN/A45.3337.0859.91Price / Book0.609.6112.156.29Net Income-$168.38M-$53.29M$3.28B$270.85M7 Day Performance-6.82%0.29%0.98%3.36%1 Month Performance-10.54%8.91%7.20%6.41%1 Year Performance-14.44%13.14%63.06%28.26% Atea Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVIRAtea Pharmaceuticals2.0702 of 5 stars$3.14-4.8%$6.00+91.1%-10.1%$261.88MN/A0.0070Short Interest ↑MLYSMineralys Therapeutics3.0042 of 5 stars$15.48+1.7%$34.40+122.2%+219.2%$1.03BN/A-4.3528Analyst ForecastPHARPharming Group2.075 of 5 stars$14.84+1.7%$30.00+102.2%+102.7%$1.02B$297.20M-114.15280News CoveragePositive NewsShort Interest ↑Gap UpNUVBNuvation Bio2.6212 of 5 stars$2.98+1.9%$7.33+146.5%+9.1%$1.02B$7.87M-4.7260Gap DownSYRESpyre Therapeutics2.3411 of 5 stars$16.49-1.4%$53.40+223.8%-44.1%$996.01M$890K-4.8573Positive NewsCRONCronos Group2.5042 of 5 stars$2.60flatN/A+18.3%$995.90M$117.61M52.00450ORICOric Pharmaceuticals4.547 of 5 stars$10.23+2.0%$17.63+72.3%+9.7%$993.57MN/A-5.4180ATAIatai Life Sciences2.8835 of 5 stars$4.58-1.5%$11.25+145.6%+268.0%$981.67M$310K-6.6480PRAXPraxis Precision Medicines2.461 of 5 stars$45.54-1.0%$85.88+88.6%-32.0%$958.42M$8.55M-3.71110Positive NewsUPBUpstream Bio1.9734 of 5 stars$17.13+2.2%$56.50+229.8%N/A$923.47M$2.37M0.0038Positive NewsURGNUrogen Pharma4.0783 of 5 stars$19.45+1.1%$32.00+64.5%+39.4%$899.84M$90.40M-5.86200News Coverage Related Companies and Tools Related Companies Mineralys Therapeutics Alternatives Pharming Group Alternatives Nuvation Bio Alternatives Spyre Therapeutics Alternatives Cronos Group Alternatives Oric Pharmaceuticals Alternatives atai Life Sciences Alternatives Praxis Precision Medicines Alternatives Upstream Bio Alternatives Urogen Pharma Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVIR) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredThe $17B signal no one expected…After SpaceX struck a $17 billion deal with EchoStar for a block of radio frequencies, tech analyst Jeff Brown...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
